

FLUOCINOLONE intravitreal implant (Iluvien®) for non-infectious uveitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of FLUOCINOLONE intravitreal implant (Iluvien®) for non-infectious uveitis

GREY

Fluocinolone intravitreal implant (Iluvien®) has recently been granted a license extension and is now indicated for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to treat non-infectious uveitis in line with local and national guidance:

- > Pan Mersey APC (September 2017): [Dexamethasone intravitreal implant \(Ozurdex®\) for treating non-infectious uveitis](#)
- > NICE (July 2017): [TA460 - Adalimumab and dexamethasone for treating non-infectious uveitis](#)
- > NICE Pathway (last updated July 2018): [Eye conditions](#)
- > Clinical Knowledge Summaries (December 2014): [Uveitis](#)

References

1. Alimera Sciences Limited. Summary of Product Characteristics: [Iluvien 190 micrograms intravitreal implant in applicator](#), 22 March 2019. Accessed online 04 April 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.